T-CAPITAL TRANSACTIONS

T-Capital Transactions

Our transactions record our involvement in representative projects, from private financing and M&A to licensing, strategic partnerships, and cross-border deals, covering various capital needs in the healthcare industry.

01 SELECTED TRANSACTIONS

Selected Transaction Cases.

Explore T-Capital's representative transaction experience.

Bingjing Intelligent Completes Two Consecutive Rounds of Financing, with T-Capital as Main Financial Advisor
Private Financing Medical Devices

Bingjing Intelligent Completes Two Consecutive Rounds of Financing, with T-Capital as Main Financial Advisor

In March 2026, the intelligent interventional ultrasound imaging platform company Bingjing Intelligent completed two consecutive rounds of financing, with a total financing amount of nearly 100 million yuan. T-Capital served as the main financial advisor for this round of financing, assisting the company in completing the financing. This case focuses on high-end medical devices, interventional ultrasound, independent research and development of core technologies, domestic substitution, and commercialization capabilities.

View Transaction →
Weixin Medical Completes Nearly 100 Million RMB Series A Financing, with T-Capital as Financial Advisor
Private Financing Medical Devices

Weixin Medical Completes Nearly 100 Million RMB Series A Financing, with T-Capital as Financial Advisor

In July 2023, Weixin Medical, an innovative medical device platform for women's health, completed a nearly 100 million RMB Series A financing. The round was led by Jinding Capital and co-invested by Taiyu Investment, with T-Capital acting as the financial advisor. The proceeds will be mainly used for product registration, advancement of clinical research, and R&D team building.

View Transaction →
ChomiX Biotech Completes Tens of Millions of Yuan in Pre-A+ Financing
Private Financing Innovative Drugs

ChomiX Biotech Completes Tens of Millions of Yuan in Pre-A+ Financing

Nanjing ChomiX Biotech Co., Ltd. has completed tens of millions of yuan in Pre-A+ financing, led by TYZS Capital, with follow-on investments from Shuimu Venture Capital and Xiaochi Capital. T-Capital acted as the financial advisor for this round and subsequent financing, providing financial advisory and consulting services to help ChomiX Biotech improve its chemical proteomics R&D platform, advance lead drug screening, and innovative drug R&D.

View Transaction →
Juvensis Therapeutics Completes Tens of Millions of Yuan in Financing, with T-Capital as Financial Advisor for This and Subsequent Rounds
Private Financing Innovative Drugs

Juvensis Therapeutics Completes Tens of Millions of Yuan in Financing, with T-Capital as Financial Advisor for This and Subsequent Rounds

On August 23, 2022, Zhejiang Juvensis Therapeutics Co., Ltd. completed tens of millions of yuan in financing, led by the Shanghai Biomedical Innovation and Transformation Fund and followed by Jinpu Xinchao Fund. T-Capital served as the financial advisor for this and subsequent financing consulting services, assisting Juvensis Therapeutics in advancing its innovative drug R&D and subsequent capital planning.

View Transaction →
Tangji Medical Completes Series B Financing, with T-Capital as Financial Advisor
Private Financing Medical Devices

Tangji Medical Completes Series B Financing, with T-Capital as Financial Advisor

Hangzhou Tangji Medical Technology Co., Ltd. has completed its Series B financing, jointly invested by Shenzhen Tojin Venture Capital and Guolian Guokang Fund, with T-Capital acting as the financial advisor. The proceeds will be used to advance the registration clinical trial of its Gastric Bypass Stent System and the R&D of innovative medical devices for metabolic diseases.

View Transaction →
Xingmou Biotech Completes Nearly 100 Million RMB Pre-A Round Financing | T-Capital Acts as Financing Advisor
Private Financing Biotechnology

Xingmou Biotech Completes Nearly 100 Million RMB Pre-A Round Financing | T-Capital Acts as Financing Advisor

Hefei Xingmou Biotechnology Co., Ltd. has completed a Pre-A round financing of nearly 100 million RMB, led by CAS-Venture, with co-investors including CSC-STAR and Isildin. T-Capital acted as the financing advisor for this round and will continue to serve as the advisor for subsequent financing. The funds will be used for the wAMD pipeline's IIT clinical trial, IND filing, new pipeline development, and high-end talent acquisition.

View Transaction →
Imbiorey Completes 230 Million RMB Series A Financing, with T-Capital as Financial Advisor for Two Consecutive Rounds
Private Financing Innovative Drugs

Imbiorey Completes 230 Million RMB Series A Financing, with T-Capital as Financial Advisor for Two Consecutive Rounds

On February 22, 2022, Imbiorey (Hangzhou) Biomedicine Co., Ltd. announced the completion of a 230 million RMB Series A financing. This round was co-led by Rui enjoy yuan Fund and Zhongnan Venture Capital Fund, with several professional investment institutions participating. T-Capital has served as the financial advisor for Imbiorey's 2020 Pre-A and this Series A round of financing.

View Transaction →
Siqin Medical Completes Strategic Financing of Tens of Millions of RMB | T-Capital Acts as Exclusive Financial Advisor
Private Financing Medical Diagnostics

Siqin Medical Completes Strategic Financing of Tens of Millions of RMB | T-Capital Acts as Exclusive Financial Advisor

On December 13, 2021, Shenzhen Siqin Medical Technology Co., Ltd. completed a strategic financing of tens of millions of RMB, led by Shandda Capital, with T-Capital acting as the exclusive financial advisor for this round. The funds from this round will be mainly used to accelerate the R&D of early screening products and business promotion.

View Transaction →
Yixin Mass Spectrometry Completes Tens of Millions of RMB in Strategic Financing, with T-Capital as Financial Advisor
Strategic Partnership Medical Devices

Yixin Mass Spectrometry Completes Tens of Millions of RMB in Strategic Financing, with T-Capital as Financial Advisor

On October 11, 2021, Yixin Mass Spectrometry completed tens of millions of RMB in strategic financing, invested by E-Town Capital, with T-Capital acting as the financial advisor for this round. Yixin Mass Spectrometry focuses on the R&D and production of clinical mass spectrometry systems and is one of the earliest companies in China to obtain a medical device registration certificate for clinical time-of-flight mass spectrometry, and has achieved multi-omics testing on a single instrument.

View Transaction →
TCAPITAL TRANSACTIONS

Considering a
healthcare transaction?

If you are considering financing, M&A, divestiture, licensing & business development, or a strategic partnership, we invite you to discuss your project with the T-Capital team.

Contact Us →